A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB plus FOLFIRI COMPARED TO BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR

被引：0

作者：

Evans, R. ^{[1
]}

Aggarwal, H. ^{[2
]}

Takundwa, R. ^{[1
]}

Chin, S. ^{[2
]}

Fenwick, E. ^{[3
]}

机构：

[1] ICON Plc, Abingdon, Oxon, England

[2] Eli Lilly & Co, Indianapolis, IN 46285 USA

[3] ICON Plc, ICON Hlth Econ, Abingdon, Oxon, England

来源：

关键词：

D O I：

10.1016/j.jval.2018.04.197

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN120

引用

页码：S31 / S31

页数：1